Determinants of T Cell Fate in Transplantation Tolerance

移植耐受中 T 细胞命运的决定因素

基本信息

  • 批准号:
    10539825
  • 负责人:
  • 金额:
    $ 71.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-01 至 2027-07-31
  • 项目状态:
    未结题

项目摘要

Transplantation is a cure for end stage organ failure, yet achieving “one transplant for life” remains elusive for many transplant recipients due to immunologic rejection. Studies in mouse and NHP models and patient populations have consistently implicated memory CD8+ T cells as playing a causal role in mediating immunosuppression-resistant allograft rejection. Thus, the identification of the molecular mechanisms that regulate memory CD8+ T cells responses remains an important goal for immunotherapy in clinical transplantation. Fc receptors, previously known only to be expressed on B cells and innate immune cells, can fine-tune immune cell activation based on the balance of activating and inhibitory Fc receptor signaling, much like T cell costimulatory and coinhibitory molecules. During the last funding cycle we identified that the inhibitory receptor FcγRIIB is also expressed on a subset of multi-functional effector/ memory CD8+ T cells in mice and in humans, and showed that FcγRIIB functionally regulates CD8+ T cell immunity in a cell- autonomous manner in both mice and in a human clinical trial. However, the mechanisms by which this occurs are still not clear. First, the signals via which FcγRIIB ligation leads to T cell death are not known. We discovered that FcγRIIB signaling on CD8+ T cells is not controlled by antibody ligation, but instead by a novel immunosuppressive cytokine fibrinogen-like 2 (Fgl2). Moreover, our additional preliminary data suggest a FcγRIIB SHIP1-dependent mechanism that leads to the induction of apoptosis. Thus, in Aim 1, we will determine the cellular source of Fgl2 that is critical for FcγRIIB-mediated CD8+ T cell apoptosis, and will use a proteomics approach to elucidate the proximal intracellular signaling molecules that associate with FcγRIIB to promote caspase 3/7 activity. Second, we made the novel observation that FcγRIIB+ CD8+ T cells exhibit increased expression of the ganglioside metabolic enzyme Gm2a, and that increased expression of Gm2a mRNA in CD8+ T cells is associated with stability on minimal immunosuppression in a cohort of human renal transplant recipients. These preliminary data form the premise for the hypothesis to be tested in Aim 2: that Gm2a is a novel regulatory pathway that regulates transplant acceptance, potentially in an FcγRIIB- dependent fashion. Finally, in Aim 3 we propose to directly measure FcγRIIB, Fgl2, and Gm2a expression in CD8+ T cells isolated from a validation cohort of human renal transplant recipients, and to determine the association between CD8+ T cell FcγRIIB and Gm2a expression and reduced alloimmunity and/or acute rejection. These data will allow us to determine the ability of FcγRIIB/Gm2a-expressing T cells to be used as a predictive biomarker to stratify the risk of rejection following transplantation. In sum, through these mechanistic and translational studies, we will elucidate the fundamental molecular and cellular pathways of FcγRIIB- mediated inhibition of CD8+ T cell responses, and their therapeutic potential to attenuate memory CD8+ T cell responses and improve outcomes in clinical transplantation.
移植是治疗终末期器官衰竭的一种方法,但实现“一次移植终身”仍然是难以捉摸的, 许多移植受者由于免疫排斥反应。在小鼠和NHP模型以及患者中的研究 人群一直暗示记忆性CD 8 + T细胞在介导 免疫抑制抵抗性同种异体移植排斥。因此,确定的分子机制, 调节记忆性CD 8 + T细胞反应仍然是临床免疫治疗的重要目标。 移植Fc受体以前只知道在B细胞和先天免疫细胞上表达, 基于激活和抑制Fc受体信号传导的平衡,微调免疫细胞激活, 如T细胞共刺激和共抑制分子。在上一个供资周期,我们确定, 抑制性受体FcγRIIB也表达于小鼠中的多功能效应/记忆CD 8 + T细胞亚群上。 在小鼠和人类中,并显示FcγRIIB在功能上调节细胞中的CD 8 + T细胞免疫。 在小鼠和人类临床试验中以自主方式进行。然而,这种情况发生的机制 还不清楚首先,FcγRIIB连接导致T细胞死亡的信号尚不清楚。我们 发现CD 8 + T细胞上的FcγRIIB信号传导不是由抗体连接控制的,而是由一种新的 免疫抑制细胞因子纤维蛋白原样2(Fgl 2)。此外,我们额外的初步数据表明, FcγRIIB依赖于SHIP 1的机制导致细胞凋亡的诱导。因此,在目标1中,我们 确定对Fcγ RIIB介导的CD 8 + T细胞凋亡至关重要的Fgl 2的细胞来源,和 将使用蛋白质组学的方法来阐明近端细胞内信号分子, FcγRIIB促进胱天蛋白酶3/7活性。第二,我们发现FcγRIIB+ CD 8 + T细胞 表现出神经节苷脂代谢酶Gm 2a的表达增加, CD 8 + T细胞中的GM 2a mRNA与人类队列中最小免疫抑制的稳定性相关 肾移植患者这些初步数据构成了目标2中检验假设的前提: Gm 2a是一种新的调节途径,可以调节移植物的接受,可能存在于FcγRIIB中, 依赖的方式。最后,在目标3中,我们提出直接测量FcγRIIB、Fgl 2和Gm 2a在小鼠中的表达。 从人肾移植受者的验证队列中分离的CD 8 + T细胞,并确定CD 8 + T细胞在人肾移植受者中的表达。 CD 8 + T细胞FcγRIIB和Gm 2a表达与同种异体免疫和/或急性 排斥反应这些数据将使我们能够确定表达FcγRIIB/Gm 2a的T细胞用作免疫调节剂的能力。 预测性生物标志物,以分层移植后排斥反应的风险。总之,通过这些机制, 和翻译研究,我们将阐明FcγRIIB的基本分子和细胞途径, 介导的CD 8 + T细胞应答抑制,以及它们减弱记忆性CD 8 + T细胞应答的治疗潜力 改善临床移植的效果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mandy L Ford其他文献

Mandy L Ford的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mandy L Ford', 18)}}的其他基金

Nanotechnology Targeting Novel CD154:CD11b Interactions for Transplant Tolerance
纳米技术靶向新型 CD154:CD11b 相互作用以提高移植耐受性
  • 批准号:
    10622211
  • 财政年份:
    2023
  • 资助金额:
    $ 71.5万
  • 项目类别:
Determinants of T Cell Fate in Transplantation Tolerance
移植耐受中 T 细胞命运的决定因素
  • 批准号:
    10672382
  • 财政年份:
    2022
  • 资助金额:
    $ 71.5万
  • 项目类别:
CD11b: A Novel Alternate Receptor for CD154 during Alloimmunity
CD11b:同种免疫期间 CD154 的新型替代受体
  • 批准号:
    10571694
  • 财政年份:
    2020
  • 资助金额:
    $ 71.5万
  • 项目类别:
CD11b: A Novel Alternate Receptor for CD154 during Alloimmunity
CD11b:同种免疫期间 CD154 的新型替代受体
  • 批准号:
    10666184
  • 财政年份:
    2020
  • 资助金额:
    $ 71.5万
  • 项目类别:
Role of TIGIT Signaling in Transplantation
TIGIT 信号传导在移植中的作用
  • 批准号:
    10228813
  • 财政年份:
    2020
  • 资助金额:
    $ 71.5万
  • 项目类别:
CD11b: A Novel Alternate Receptor for CD154 during Alloimmunity
CD11b:同种免疫期间 CD154 的新型替代受体
  • 批准号:
    10356115
  • 财政年份:
    2020
  • 资助金额:
    $ 71.5万
  • 项目类别:
CD11b: A Novel Alternate Receptor for CD154 during Alloimmunity
CD11b:同种免疫期间 CD154 的新型替代受体
  • 批准号:
    10728916
  • 财政年份:
    2020
  • 资助金额:
    $ 71.5万
  • 项目类别:
Memory T Cell Cosigning Pathways in Sepsis-Induced Immune Dysregulation
脓毒症引起的免疫失调中的记忆 T 细胞协同信号通路
  • 批准号:
    10079469
  • 财政年份:
    2015
  • 资助金额:
    $ 71.5万
  • 项目类别:
Memory T Cell Cosigning Pathways in Sepsis-Induced Immune Dysregulation
脓毒症引起的免疫失调中的记忆 T 细胞协同信号通路
  • 批准号:
    9887580
  • 财政年份:
    2015
  • 资助金额:
    $ 71.5万
  • 项目类别:
Memory T Cell Cosigning Pathways in Sepsis-Induced Immune Dysregulation
脓毒症引起的免疫失调中的记忆 T 细胞协同信号通路
  • 批准号:
    10323009
  • 财政年份:
    2015
  • 资助金额:
    $ 71.5万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 71.5万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 71.5万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 71.5万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 71.5万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 71.5万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 71.5万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 71.5万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 71.5万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 71.5万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 71.5万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了